Eisai Creates US Subsidiary H3 Biomedicine with up to $200M

Jan 28, 2011

NEW YORK (GenomeWeb News) – Japanese drug firm Eisai has launched US subsidiary H3 Biomedicine with up to $200 million in funding to develop new oncology drugs based on patient genetic information.

Based in Cambridge, Mass., H3 Biomedicine aims to take a personalized medicine approach to developing such drugs by leveraging new insights into the genetic basis of cancer and advances in modern chemistry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Who Are You?

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

'Problematic'

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Republicans Take on Peer Review

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

This Week in Science

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

Main menu